Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Search
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire
Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US
Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).
Evolving the Unwearable Collection
Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™
A legacy in the making: Working together to spark meaningful change
Discover Jim’s passion for being an advocate for meaningful causes.
Onboarding
Onboarding
Focus on Alliance Management
Focus on Alliance Management
From the archives: Maria Plum’s story as a pioneer of her time
Maria Plum was one of the first female lawyers in Germany, and she served as legal counselor for our company starting in the 1930s. Read account of her story written by Katrin Lege, Head of the Boehringer Ingelheim Company Archives, who discovered details
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Ann-Kathrin Koller
Career choices, culture, the future and more with Ann-Kathrin Koller.
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Purchasing
Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US
BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.
Growing fresh produce for a cause at our U.S. headquarters
Growing fresh produce for a cause at our U.S. headquarters
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.